Ascendis Pharma (ASND) Reports VISEN’s Phase 3 Chinese Trial Results are Consistent with Ascendis Pharma’s Phase 3 Height Trial

Ascendis Pharma A/S (Nasdaq: ASND) announced today that results from VISEN Pharmaceuticals’ Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharma’s earlier multi-national Phase 3 trial. VISEN Pharmaceuticals’ Phase 3 trial achieved its primary endpoint, with pediatric GHD patients treated with once-weekly TransCon hGH demonstrating greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone. In both Ascendis Pharma’s and VISEN Pharmaceuticals’ Phase 3 trials, TransCon hGH – now approved in both the U.S. and EU as a once-weekly treatment for pediatric GHD – demonstrated statistical non-inferiority and superiority on the primary endpoint with comparable safety and tolerability to daily growth hormone.

“Ascendis Pharma congratulates VISEN Pharmaceuticals for successfully completing its first Phase 3 clinical trial of a TransCon product candidate in China,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations.”

Results of the Phase 3 trial of TransCon hGH in China were reported by VISEN Pharmaceuticals, whose press release can be viewed on www.visenpharma.com.

You May Also Be Interested In

• Lumen Technologies (LUMN) to cut 7% staff
• Vertex (VERX) Announces Pricing of Upsized $300 Mln Convertible Senior Notes Offering
• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab